196 related articles for article (PubMed ID: 17729189)
1. Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure.
Wehrens XH
Curr Opin Investig Drugs; 2007 Sep; 8(9):769-77. PubMed ID: 17729189
[TBL] [Abstract][Full Text] [Related]
2. Novel analogues of Istaroxime, a potent inhibitor of Na(+),K(+)-ATPase: Synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold.
Gobbini M; Armaroli S; Banfi L; Benicchio A; Carzana G; Ferrari P; Giacalone G; Marazzi G; Moro B; Micheletti R; Sputore S; Torri M; Zappavigna MP; Cerri A
Bioorg Med Chem; 2010 Jun; 18(12):4275-99. PubMed ID: 20494582
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
[TBL] [Abstract][Full Text] [Related]
4. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
Micheletti R; Palazzo F; Barassi P; Giacalone G; Ferrandi M; Schiavone A; Moro B; Parodi O; Ferrari P; Bianchi G
Am J Cardiol; 2007 Jan; 99(2A):24A-32A. PubMed ID: 17239701
[TBL] [Abstract][Full Text] [Related]
5. Istaroxime: a new luso-inotropic agent for heart failure.
Mattera GG; Lo Giudice P; Loi FM; Vanoli E; Gagnol JP; Borsini F; Carminati P
Am J Cardiol; 2007 Jan; 99(2A):33A-40A. PubMed ID: 17239702
[TBL] [Abstract][Full Text] [Related]
6. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial.
Shah SJ; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Grzybowski J; Valentini G; Sabbah HN; Gheorghiade M;
Am Heart J; 2009 Jun; 157(6):1035-41. PubMed ID: 19464414
[TBL] [Abstract][Full Text] [Related]
7. Novel analogues of istaroxime, a potent inhibitor of Na+,K+-ATPase: synthesis and structure-activity relationship.
Gobbini M; Armaroli S; Banfi L; Benicchio A; Carzana G; Fedrizzi G; Ferrari P; Giacalone G; Giubileo M; Marazzi G; Micheletti R; Moro B; Pozzi M; Scotti PE; Torri M; Cerri A
J Med Chem; 2008 Aug; 51(15):4601-8. PubMed ID: 18637667
[TBL] [Abstract][Full Text] [Related]
8. Istaroxime: an investigational luso-inotropic agent for acute heart failure syndromes.
Gheorghiade M; Sabbah HN
Am J Cardiol; 2007 Jan; 99(2A):1A-3A. PubMed ID: 17239700
[No Abstract] [Full Text] [Related]
9. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure.
Gheorghiade M; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Valentini G; Sabbah HN;
J Am Coll Cardiol; 2008 Jun; 51(23):2276-85. PubMed ID: 18534276
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
[TBL] [Abstract][Full Text] [Related]
11. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.
Ghali JK; Smith WB; Torre-Amione G; Haynos W; Rayburn BK; Amato A; Zhang D; Cowart D; Valentini G; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):47A-56A. PubMed ID: 17239705
[TBL] [Abstract][Full Text] [Related]
12. Istaroxime in heart failure new hope or more hype.
Dec GW
J Am Coll Cardiol; 2008 Jun; 51(23):2286-8. PubMed ID: 18534277
[No Abstract] [Full Text] [Related]
13. Chronic istaroxime improves cardiac function and heart rate variability in cardiomyopathic hamsters.
Lo Giudice P; Mattera GG; Gagnol JP; Borsini F
Cardiovasc Drugs Ther; 2011 Apr; 25(2):133-8. PubMed ID: 21287411
[TBL] [Abstract][Full Text] [Related]
14. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
Khan H; Metra M; Blair JE; Vogel M; Harinstein ME; Filippatos GS; Sabbah HN; Porchet H; Valentini G; Gheorghiade M
Heart Fail Rev; 2009 Dec; 14(4):277-87. PubMed ID: 19238540
[TBL] [Abstract][Full Text] [Related]
15. Modulators of Na/K-ATPase: a patent review.
Wang HY; O'Doherty GA
Expert Opin Ther Pat; 2012 Jun; 22(6):587-605. PubMed ID: 22595010
[TBL] [Abstract][Full Text] [Related]
16. Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output.
Gheorghiade M; Ambrosy AP; Ferrandi M; Ferrari P
Discov Med; 2011 Aug; 12(63):141-51. PubMed ID: 21878191
[TBL] [Abstract][Full Text] [Related]
17. Diverse toxicity associated with cardiac Na+/K+ pump inhibition: evaluation of electrophysiological mechanisms.
Rocchetti M; Besana A; Mostacciuolo G; Ferrari P; Micheletti R; Zaza A
J Pharmacol Exp Ther; 2003 May; 305(2):765-71. PubMed ID: 12606646
[TBL] [Abstract][Full Text] [Related]
18. Targeting SERCA2a as an innovative approach to the therapy of congestive heart failure.
Ferrari P; Micheletti R; Valentini G; Bianchi G
Med Hypotheses; 2007; 68(5):1120-5. PubMed ID: 17113239
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design and synthesis of novel potent Na+,K+ -ATPase inhibitors derived from a 5alpha,14alpha-androstane scaffold as positive inotropic compounds.
De Munari S; Cerri A; Gobbini M; Almirante N; Banfi L; Carzana G; Ferrari P; Marazzi G; Micheletti R; Schiavone A; Sputore S; Torri M; Zappavigna MP; Melloni P
J Med Chem; 2003 Aug; 46(17):3644-54. PubMed ID: 12904068
[TBL] [Abstract][Full Text] [Related]
20. Istaroxime, a positive inotropic agent devoid of proarrhythmic properties in sensitive chronic atrioventricular block dogs.
Bossu A; Kostense A; Beekman HDM; Houtman MJC; van der Heyden MAG; Vos MA
Pharmacol Res; 2018 Jul; 133():132-140. PubMed ID: 29753687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
